Evidence map›Paper›PMID 25822705›Full record

ArticleWorld journal of urology2015

Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS).

Hanna Vasarainen, Jolanda Salman, Heidi Salminen, Riccardo Valdagni, Tom Pickles, Chris Bangma, Monique J Roobol, Antti Rannikko

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Biomarkers in localized prostate cancer.Future oncology (London, England) · 2016
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hanna VasarainenDepartment of Urology, Peijas Hospital, Helsinki University Central Hospital and University of Helsinki, P.O. Box 900, 00029, Helsinki, Finland. hanna.vasarainen@hus.fi.
Jolanda SalmanDepartment of Urology, Erasmus Medical Center, Rotterdam, The Netherlands.
Heidi SalminenDepartment of Urology, Peijas Hospital, Helsinki University Central Hospital and University of Helsinki, P.O. Box 900, 00029, Helsinki, Finland.
Riccardo ValdagniDepartment of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Tom PicklesDepartment of Radiation Oncology and Developmental Radiotherapeutics, University of British Columbia, and BC Cancer Agency, Vancouver, Canada.
Chris BangmaDepartment of Urology, Erasmus Medical Center, Rotterdam, The Netherlands.
Monique J RoobolDepartment of Urology, Erasmus Medical Center, Rotterdam, The Netherlands.
Antti RannikkoDepartment of Urology, Peijas Hospital, Helsinki University Central Hospital and University of Helsinki, P.O. Box 900, 00029, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the utility of percentage of free serum PSA (%fPSA) as a predictor of adverse rebiopsy findings, treatment change and radical prostatectomy (RP) findings in a prospective active surveillance (AS) trial.

methodsPatients enrolled in the global PRIAS study with baseline %fPSA available were included. Putative baseline predictors (e.g. PSA, %fPSA) of adverse rebiopsy findings were explored using logistic regression analysis. Association of variables with treatment change and RP findings over time were evaluated with Cox regression analysis. Active treatment-free survival was assessed with a Kaplan-Meier method.

resultsOf 3701 patients recruited to PRIAS, 939 had %fPSA measured at study entry. Four hundred and thirty-eight of them had %fPSA available after 1 year. Median follow-up was 17.2 months. First rebiopsy results were available for 595 patients and of those, 144 (24.2 %) had adverse findings. A total of 283 (30.1 %) patients discontinued surveillance, of those 181 (64.0 %) due to protocol-based reasons. Although median %fPSA values were significantly lower in patients who changed treatment, according to the multivariate regression analysis, initial %fPSA value was not predictive for treatment change or adverse rebiopsy findings. However, the probability of discontinuing AS was significantly lower in patients with "favourable" initial %fPSA characteristics and %fPSA during follow-up (initial %fPSA ≥15 and positive %fPSA velocity) compared to those with "adverse" %fPSA characteristics (initial %fPSA <15 and negative %fPSA velocity).

conclusionsDiagnostic %fPSA provides no additional prognostic value when compared to other predictors already in use in AS protocols. However, %fPSA velocity during surveillance may aid in predicting the probability for future treatment change.

Indexed as

AgedBiomarkers, TumorBiopsyEarly Detection of CancerFollow-Up StudiesGlobal HealthHumansIncidenceMaleMiddle AgedNeoplasm StagingPredictive Value of TestsPrognosisProspective StudiesProstate-Specific AntigenProstatic NeoplasmsBiomarkers, TumorProstate-Specific AntigenActive surveillanceFree prostate-specific antigenProstate cancerProstate-specific antigen

Identifiers

PMID25822705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.